ArticleBiochemical genetics2023
Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer.
Article in Biochemical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type-2-diabetes (T2D) and pancreatic cancer (PC) are both common diseases globally. Although T2D is reported as the adverse factor for predicting PC prognosis, its pathophysiology and relation with PC remain unknown. This study focused on exploring differentially expressed genes (DEGs) as well as their functional roles in T2D and PC, aiming to reveal the underlying association between the T2D and PC. To identify DEGs in T2D and PC, this study analyzed four microarray datasets obtained from Gene Expression Omnibus (GEO) database. Then, this work carried out enrichment as well as protein-protein interaction (PPI) network analysis for exploring DEGs-enriched functions and pathway. Besides, expression of hub genes was explored. TISIDB database was adopted to analyze the correlations among key gene and immune characteristics. Finally, the key gene expression was confirmed in vitro. DEGs were first screened from gene expression profiles of T2D and PC datasets, respectively. Then 135 common genes were identified in these four datasets. Based on functional analysis, common DEGs were mostly related to hormone secretion and metabolism pathways. Four hub genes were up-regulated, among which, MAFB was the most significant potential biomarker for PC. MAFB expression was strongly correlated with chemokines, chemokine receptors and immunomodulators. Finally, RT-qPCR was conducted to demonstrate the MAFB expression in T2D and PC. This study identified 15 hub genes with significant effects on the association of T2D with PC, and MAFB gene might be a biomarker for PC and had potential treatment value for PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.